The Food and Drug Administration yesterday authorized the Novavax COVID-19 vaccine for emergency use in adults, as recommended last month by its vaccine advisory committee. If the Centers for Disease Control and Prevention also recommends the vaccine for adults, the protein-based vaccine would offer an option to individuals who may have an allergic reaction to or prefer not to receive an mRNA vaccine. The departments of Health and Human Services and Defense this month secured 3.2 million doses of the vaccine to give states, federal pharmacy partners and federally qualified health centers. The two-dose vaccine can be stored at 2-8 degrees Celsius (about 36-46 degrees Fahrenheit), enabling the use of existing vaccine supply and cold chain channels.
 

Related News Articles

Headline
Pfizer has submitted a request for the Food and Drug Administration to authorize a 10-microgram booster dose of its bivalent COVID-19 vaccine booster for…
Headline
Health care providers who treat uninsured or underinsured patients with commercially procured bebtelovimab, a COVID-19 monoclonal antibody therapy for…
Headline
Moderna Friday submitted its request that the Food and Drug Administration authorize for emergency use its bivalent COVID-19 vaccine for children and…
Headline
AHA will co-host a Sept. 27 Facebook Live event with AdventHealth on the importance of getting children vaccinated and boosted against COVID-19, which will…
Headline
Insured and uninsured Americans can receive the new bivalent Pfizer or Moderna COVID-19 booster and other COVID-19 vaccines at no cost as long as the federal…
Headline
The Biden Administration will make over 170 million doses of the bivalent COVID-19 vaccine booster available to Americans for free at pharmacies, doctor’s…